InsidersTradesSigma
Total declarations
Companies
▲ Purchases (31 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
31
Disclosed sells
1
T+90 hit rate
63%
T+90 mean return
+27.0%
Across 16 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Akkaraju Srinivas, Director. Officer active across 8 companies, notably Intercept Pharmaceuticals, INC.. Cumulatively, 60 filings have been logged. Breakdown: 31 buys · 1 sell. Total volume traded: €131.8m. Activity tracked since 27 May 2021. The latest transaction was disclosed on 4 June 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Akkaraju Srinivas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations60 total
3,553 sharesCommon StockSEC:0001253170-26-000011:0
6,839 shares0Common StockSEC:0001104659-26-071422:0
244,300 shares@ US$4.8319.2% of flowCommon StockSEC:0001231919-26-000532:0
Canonical exit: 18 Aug 2026 (T+90)
66,906 shares0Common StockSEC:0001231919-26-000532:1
14,937 shares0Common StockSEC:0001231919-26-000532:2
4,471 shares0Common StockSEC:0001231919-26-000532:3
6,200 shares0Common StockSEC:0001933414-26-000040:0
479,847 shares@ US$10.4280.8% of flowCommon StockSEC:0001231919-26-000166:0
Canonical exit: 18 Mar 2026 (T+90)
588,235 shares@ US$17.0024.7% of flowCommon StockSEC:0001253170-26-000004:0
Canonical exit: 9 Apr 2026 (T+90)
1,500,000 shares@ US$10.0070.8% of flowCommon StockSEC:0001231919-25-000652:0
12,796 shares@ US$39.310.9% of flowCommon StockSEC:0001253170-25-000025:0
Canonical exit: 5 Jan 2026 (T+90)
12,400 shares@ US$40.180.8% of flowCommon StockSEC:0001253170-25-000025:1
Canonical exit: 5 Jan 2026 (T+90)
4,403 shares@ US$40.970.3% of flowCommon StockSEC:0001253170-25-000025:2
Canonical exit: 5 Jan 2026 (T+90)
1,064,804 shares@ US$7.3513.1% of flowCommon StockSEC:0001253170-25-000025:3
64,969 shares@ US$8.951.4% of flowCommon StockSEC:0001253170-25-000021:0
Canonical exit: 5 Mar 2026 (T+90)
70,028 shares@ US$10.011.7% of flowCommon StockSEC:0001253170-25-000021:1
Canonical exit: 5 Mar 2026 (T+90)
51,380 shares@ US$10.731.4% of flowCommon StockSEC:0001253170-25-000021:2
Canonical exit: 5 Mar 2026 (T+90)
96,000 shares@ US$7.551.7% of flowCommon StockSEC:0001253170-25-000019:0
Canonical exit: 2 Mar 2026 (T+90)
48,537 shares@ US$7.640.9% of flowCommon StockSEC:0001253170-25-000017:0
Canonical exit: 24 Feb 2026 (T+90)
125,743 shares@ US$7.202.1% of flowCommon StockSEC:0001253170-25-000014:0
Canonical exit: 18 Feb 2026 (T+90)
914 shares@ US$5.510.0% of flowCommon StockSEC:0001253170-25-000011:0
Canonical exit: 15 Feb 2026 (T+90)
276,179 shares@ US$5.253.5% of flowCommon StockSEC:0001253170-25-000008:0
Canonical exit: 11 Feb 2026 (T+90)
11,011 shares@ US$35.610.7% of flowCommon StockSEC:0001253170-25-000006:0
Canonical exit: 1 Jan 2026 (T+90)
56,703 shares@ US$36.743.5% of flowCommon StockSEC:0001253170-25-000006:1
Canonical exit: 1 Jan 2026 (T+90)
319,700 shares@ US$37.4220.1% of flowCommon StockSEC:0001253170-25-000006:2
Canonical exit: 1 Jan 2026 (T+90)
25 of 60 declarations
About Akkaraju Srinivas
AKKARAJU SRINIVAS is Administrateur at ALUMIS INC., Scholar Rock Holding Corp, Kalaris Therapeutics, Inc., Mineralys Therapeutics, Inc., Syros Pharmaceuticals, Inc. and Chinook Therapeutics, INC. He has 60 filings in total. Across the 60 sampled recent filings, the period runs from 2021-06-01 to 2026-07-02, with EUR 119016785 of buys and EUR 12778178 of sells, and the most frequent transaction nature is Acquisition.
